Board member, Todd C. Peterson, Ph.D., serves as Chair of the CTAB

董事会成员Todd C.Peterson博士担任CTAB主席

New appointments include David Smoller, Ph.D., serial entrepreneur and General Partner at Cultivation Capital Life Sciences and Stephen Turner, Ph.D., Founder at PacBio

新任命的人选包括培养资本生命科学公司（Culturation Capital Life Sciences）的连续企业家兼普通合伙人大卫·斯莫勒（David Smoller）博士和PacBio创始人斯蒂芬·特纳（Stephen Turner）博士

SAN DIEGO, Feb. 13, 2024 /PRNewswire/ -- Molecular Assemblies, Inc., ('MAI' or the 'Company') a pioneer in the field of enzymatic DNA synthesis, today announced the addition of two industry leaders to its Commercial-Technology Advisory Board (CTAB), which includes experts in the commercialization of nucleic acid technologies and innovative life science product solutions.

圣地亚哥，2024年2月13日/PRNewswire/--Molecular Assemblys，Inc.（“MAI”或“公司”）是酶促DNA合成领域的先驱，今天宣布其商业技术咨询委员会（CTAB）增加了两个行业领导者，其中包括核酸技术商业化和创新生命科学产品解决方案方面的专家。

The CTAB provides strategic guidance on the Company's commercialization strategies for Molecular Assemblies' Fully Enzymatic Synthesis™ (FES™ technology, which accelerates the production of long, pure, and accurate DNA to power the next generation of therapeutics, diagnostics, agricultural products, and industrial materials..

CTAB为公司的分子组装全酶合成（FES™技术）商业化战略提供了战略指导，该技术加速了长、纯、准确DNA的生产，为下一代治疗、诊断、农产品和工业材料提供动力。。

'With the deep knowledge, wisdom, and experience commercializing transformative life science products, the CTAB enables Molecular Assemblies to identify emerging opportunities and trends in the life sciences industry that can be solved with our breakthrough nucleic acid-based products,' said Larry Stambaugh, Board Chair of Molecular Assemblies.

“凭借将变革性生命科学产品商业化的深厚知识、智慧和经验，CTAB使分子组装能够识别生命科学行业的新兴机遇和趋势，这些机遇和趋势可以通过我们突破性的核酸产品来解决，”分子组装董事会主席拉里·斯坦博（LarryStambaugh）说。

'We continue to receive strong feedback from our early customers who are utilizing our breakthrough long, highly pure oligonucleotides to drive scientific discovery in high growth applications such as CRISPR gene editing, therapeutic development, and protein engineering, and we look forward to expanding our commercial efforts to supply the industry with oligos and genes they desire.'.

“我们继续收到早期客户的强烈反馈，他们正在利用我们突破性的长，高纯度寡核苷酸来推动CRISPR基因编辑，治疗开发和蛋白质工程等高增长应用中的科学发现，我们期待着扩大我们的商业努力，为行业提供他们想要的寡核苷酸和基因。”。

'Molecular Assemblies is helping accelerate the life science industry by removing one of the largest bottlenecks in R&D – the availability of long, pure, accurate oligonucleotides,' said Todd C. Peterson, Ph.D., CTAB Chair and MAI Board Director. 'By bringing together proven experts with a track record of successfully working across life science tools and therapeutic modalities, the CTAB will enable Molecular Assemblies to leverage its leading enzymatic DNA synthesis technology into commercial success.'.

CTAB主席、MAI董事会主任、博士托德·彼得森（ToddC.Peterson）说，分子组装通过消除研发中最大的瓶颈之一——长、纯、准确的寡核苷酸的可用性，帮助加速了生命科学行业的发展通过汇集具有跨生命科学工具和治疗方式成功工作记录的成熟专家，CTAB将使分子组装能够利用其领先的酶促DNA合成技术取得商业成功。”。

MAI's Commercial Technology Advisory Board

MAI的商业技术咨询委员会

Todd C. Peterson, Ph.D., CTAB Chair, has more than 35 years of experience in biotechnology and life sciences research and development across the areas of molecular and cell biology, nucleic acids, and genomics product and technology development. He is currently Founder and Principal at GenApex Bio, a life sciences Board service and advisory practice.

CTAB主席Todd C.Peterson博士在分子和细胞生物学、核酸以及基因组学产品和技术开发领域的生物技术和生命科学研究与开发方面拥有35年以上的经验。他目前是生命科学委员会服务和咨询机构GenApex Bio的创始人和负责人。

Previously Dr. Peterson has held the following roles: Chief Scientific Officer at The Allen Institute, Chief Technology Officer at Synthetic Genomics, Inc., leading Genomics and Synthetic Biology R&D at Invitrogen/Life Technologies (now Thermo Fisher Scientific), and R&D positions at Genicon Sciences, Trega Biosciences, Hybritech, and Gen-Probe, where he focused on technology research, product development, and commercialization. .

此前，彼得森博士曾担任以下职务：艾伦研究所首席科学官，合成基因组公司首席技术官，Invitrogen/Life Technologies（现为Thermo Fisher Scientific）领导基因组学和合成生物学研发，以及Genicon Sciences，Trega Biosciences，Hybritech和Gen Probe的研发职位，他专注于技术研究，产品开发和商业化。。

David Smoller, Ph.D., is a General Partner of Cultivation Capital Life Sciences Fund, a venture fund focused on life science investing with companies in the therapeutic, diagnostic instruments, healthcare IT, research tools, and agriculture sectors. He also serves as an Entrepreneur in Residence at St.

David Smoller博士是Culturation Capital Life Sciences Fund的普通合伙人，该基金是一家专注于生命科学的风险基金，与治疗，诊断仪器，医疗保健IT，研究工具和农业部门的公司进行投资。他还担任圣路易斯大学的常驻企业家。

Louis BioGenerator, the investment arm of BioSTL. His extensive experience includes leadership roles at Sigma-Aldrich and Genome Systems, where he made significant contributions to the genomics field. Dr. Smoller co-founded Solis Agrosciences, Panome Bio, and Canopy Biosciences (acquired by Bruker Corporation).

Louis BioGenerator，BioSTL的投资部门。他丰富的经验包括在Sigma-Aldrich和Genome Systems担任领导职务，在那里他对基因组学领域做出了重大贡献。斯莫勒博士共同创立了Solis Agrosciences、Panome Bio和Canopy Biosciences（被布鲁克公司收购）。

His earlier ventures include SAGE Labs (acquired by Horizon Discovery) and ProteoPlex, a proteomic technology pioneer..

他早期的投资包括SAGE实验室（被Horizon Discovery收购）和蛋白质组学技术先驱ProteoPlex。。

Stephen Turner, Ph.D., founded PacBio.He was a member of the project team at Cornell which developed the technology now employed by PacBio and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. Dr. Turner is the author of more than 300 scientific papers in fields, ranging from DNA sequencing technology and biophysics to genomics and epigenomics, and is listed as the inventor on more than 50 U.S.

斯蒂芬·特纳（StephenTurner）博士创立了PacBio。他是康奈尔大学（Cornell）项目团队的成员，该团队开发了PacBio目前使用的技术，并且是《科学》杂志（2003年1月31日）封面故事的合著者，该文将该技术介绍给了科学界。特纳博士在DNA测序技术、生物物理学、基因组学和表观基因组学等领域发表了300多篇科学论文，并被列为美国50多个国家的发明家。

patents and numerous published patent applications..

专利和众多已发布的专利申请。。

Molecular Assemblies' FES™ TechnologyMolecular Assemblies' Fully Enzymatic Synthesis™ (FES™) is the foundation of their approach to create long, high quality, sequence specific DNA composed of more than 300 base pairs and complex sequences not available today. The FES technique mimics the way DNA is naturally produced and decreases the need for lengthy and expensive post-synthesis purification.

分子组装的FES™技术分子组装的全酶促合成™（FES™）是其创建长，高质量，序列特异性DNA的方法的基础，该DNA由300多个碱基对和目前尚不可用的复杂序列组成。FES技术模仿了DNA自然产生的方式，减少了对冗长而昂贵的合成后纯化的需求。

Synthetic synthesis of DNA chains is the premise of experiments in the biotechnology and health science sectors. This patented platform is powering the exciting next generation of DNA-based products. Molecular Assemblies is now offering access to long, custom oligonucleotides synthesized with the Company's FES technology enabling customers to accelerate their research in CRISPR gene editing, protein engineering, and NGS probes and controls. Learn more about getting access to the FES technology by visiting: http://www.molecularassemblies.com/now-available..

DNA链的合成是生物技术和健康科学领域实验的前提。这个专利平台正在为令人兴奋的下一代基于DNA的产品提供动力。Molecular Assembly现在可以使用该公司的FES技术合成长的定制寡核苷酸，从而使客户能够加速其在CRISPR基因编辑，蛋白质工程以及NGS探针和对照方面的研究。通过访问了解更多有关访问FES技术的信息：http://www.molecularassemblies.com/now-available..

About Molecular AssembliesMolecular Assemblies, Inc. is a private life sciences company advancing their proprietary enzymatic DNA synthesis technology that is designed to significantly elevate the future generation of DNA-based products. The company's patented Fully Enzymatic Synthesis™ (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably, including sequences not available today.

关于分子组装分子组装公司（About Molecular AssembliesMolecular Assemblies，Inc.）是一家私营生命科学公司，致力于推进其专有的酶促DNA合成技术，旨在显着提升未来一代基于DNA的产品。该公司的专利全酶合成™（或FES™）基于自然界制造DNA的方式制造DNA，可靠，经济且可持续地生产出长，高质量，序列特异性DNA，包括目前无法获得的序列。

FES technology will enable the writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of DNA for data information storage, nanomachines, and bio-based electronics. Molecular Assemblies is headquartered in San Diego. For more information, visit molecularassemblies.com..

FES技术将使许多行业的DNA书写成为可能，包括工业合成生物学和精密医学，以及DNA在数据信息存储，纳米机器和生物电子领域的新兴应用。Molecular Assembly总部位于圣地亚哥。有关更多信息，请访问molecularassemblies.com。。

ContactsCompany: Ben Johnson, Senior Director of Sales and Marketing, [email protected]Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., [email protected], +1.858.344.8091

联系人公司：销售和营销高级总监Ben Johnson，[电子邮件保护]媒体：Jessica Yingling博士，Little Dog Communications Inc.，[电子邮件保护]，+1.858.344.8091

SOURCE Molecular Assemblies, Inc.

源分子组装公司。